Cargando…

An update on treatment options for pancreatic adenocarcinoma

Pancreatic cancer is one of the most lethal solid organ tumors. Due to the rising incidence, late diagnosis, and limited treatment options, it is expected to be the second leading cause of cancer deaths in high income countries in the next decade. The multidisciplinary treatment of this disease depe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lambert, Aurélien, Schwarz, Lilian, Borbath, Ivan, Henry, Aline, Van Laethem, Jean-Luc, Malka, David, Ducreux, Michel, Conroy, Thierry
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6763942/ https://www.ncbi.nlm.nih.gov/pubmed/31598142 http://dx.doi.org/10.1177/1758835919875568

Ejemplares similares

Neoadjuvant Treatment Strategies in Resectable Pancreatic Cancer
por: Lambert, Aurélien, et al.
Publicado: (2021)

Preoperative treatment with mFOLFIRINOX or Gemcitabine/Nab-paclitaxel +/- isotoxic high-dose stereotactic body Radiation Therapy (iHD-SBRT) for borderline resectable pancreatic adenocarcinoma (the STEREOPAC trial): study protocol for a randomised comparative multicenter phase II trial
por: Bouchart, Christelle, et al.
Publicado: (2023)

A real-world analysis on the efficacy and tolerability of liposomal irinotecan plus 5-fluorouracil and folinic acid in metastatic pancreatic ductal adenocarcinoma in Belgium
por: Verbruggen, Lise, et al.
Publicado: (2023)

EUS-guided radiofrequency ablation of pancreatic/peripancreatic tumors and oligometastatic disease: an observational prospective multicenter study
por: Figueiredo Ferreira, Mariana, et al.
Publicado: (2022)

Expert opinion on management of pancreatic exocrine insufficiency in pancreatic cancer
por: Roeyen, G., et al.
Publicado: (2022)

Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study
por: Heinrich, Stefan, et al.
Publicado: (2019)

What Should Guide the Performance of Venous Resection During Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma with Venous Contact?
por: Navez, Julie, et al.
Publicado: (2021)

Response to FOLFIRINOX by gender in patients with metastatic pancreatic cancer: Results from the PRODIGE 4/ ACCORD 11 randomized trial
por: Lambert, Aurélien, et al.
Publicado: (2017)

Precision Medicine in Pancreatic Ductal Adenocarcinoma: The Impact of Targeted Therapies on Survival of Patients Harboring Actionable Mutations
por: Tarabay, Anthony, et al.
Publicado: (2023)

Preneoplastic Lesions in Surgical Specimens Do Not Worsen the Prognosis of Patients Who Underwent Surgery for Pancreatic Adenocarcinoma: Post-Hoc Analysis of the PRODIGE 24-CCTG PA 6 Trial
por: Legrand, Théo, et al.
Publicado: (2022)

Isotoxic high-dose stereotactic body radiotherapy integrated in a total multimodal neoadjuvant strategy for the treatment of localized pancreatic ductal adenocarcinoma
por: Bouchart, Christelle, et al.
Publicado: (2021)

Treatment of Pancreatic Cancer: What Can We Really Predict Today?
por: Bachet, Jean-Baptiste, et al.
Publicado: (2011)

Aquaporins Involvement in Pancreas Physiology and in Pancreatic Diseases
por: Arsenijevic, Tatjana, et al.
Publicado: (2019)

Treatment Options for Germline BRCA-Mutated Metastatic Pancreatic Adenocarcinoma
por: Grzelak, Doreen
Publicado: (2021)

SMAD4 Positive Pancreatic Ductal Adenocarcinomas Are Associated with Better Outcomes in Patients Receiving FOLFIRINOX-Based Neoadjuvant Therapy
por: Racu, Marie-Lucie, et al.
Publicado: (2023)

Advanced pancreatic ductal adenocarcinoma - Complexities of treatment and emerging therapeutic options
por: Diwakarla, Chandra, et al.
Publicado: (2017)

Systemic treatment for inoperable pancreatic adenocarcinoma: review and update
por: Chan, Stephen L., et al.
Publicado: (2014)

Multidetector computer tomography in the pancreatic adenocarcinoma assessment: an update
por: Granata, Vincenza, et al.
Publicado: (2016)

Pancreatic Ductal Adenocarcinoma Arising in Young and Old Patients Displays Similar Molecular Features
por: Raffenne, Jérôme, et al.
Publicado: (2021)

An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma
por: Péron, Julien, et al.
Publicado: (2016)

Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options
por: Kabacaoglu, Derya, et al.
Publicado: (2018)

Focus on Therapeutic Options for Surgically Resectable Pancreatic Adenocarcinoma Based on Novel Biomarkers
por: Olivari, Alessandro, et al.
Publicado: (2023)

Development of a Clinical–Biological Model to Assess Tumor Progression in Metastatic Pancreatic Cancer: Post Hoc Analysis of the PRODIGE4/ACCORD11 Trial
por: Egea, Julie, et al.
Publicado: (2022)

Therapeutic Options for Coronavirus Disease 2019 (COVID-19) - Modulation of Type I Interferon Response as a Promising Strategy?
por: Mary, Aurélien, et al.
Publicado: (2020)

Immunotherapy in Advanced Biliary Tract Cancers
por: Boilève, Alice, et al.
Publicado: (2021)

Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study)
por: Schwarz, Lilian, et al.
Publicado: (2018)

Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study
por: Demols, A, et al.
Publicado: (2006)

Correction to: Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study)
por: Schwarz, Lilian, et al.
Publicado: (2020)

High expression of CXCR4 may predict poor survival in resected pancreatic adenocarcinoma
por: Maréchal, R, et al.
Publicado: (2009)

High expression of CXCR4 may predict poor survival in resected pancreatic adenocarcinoma
por: Maréchal, R, et al.
Publicado: (2010)

Novel strategies using modern radiotherapy to improve pancreatic cancer outcomes: toward a new standard?
por: Bouchart, Christelle, et al.
Publicado: (2020)

Pancreatic Cancer Meets Human Microbiota: Close Encounters of the Third Kind
por: Arsenijevic, Tatjana, et al.
Publicado: (2021)

Postoperative hepatic arterial chemotherapy in high-risk patients as adjuvant treatment after resection of colorectal liver metastases - a randomized phase II/III trial – PACHA-01 (NCT02494973)
por: Goéré, Diane, et al.
Publicado: (2018)

Impact of the COVID-19 pandemic on disease stage and treatment for patients with pancreatic adenocarcinoma: A French comprehensive multicentre ambispective observational cohort study (CAPANCOVID)
por: Brugel, Mathias, et al.
Publicado: (2022)

EUS-guided placement of fiducial markers for stereotactic body radiation therapy in pancreatic cancer: feasibility, security and a new quality score
por: Figueiredo, Mariana, et al.
Publicado: (2021)

Modeling human pancreatic ductal adenocarcinoma for translational research: current options, challenges, and prospective directions
por: Suri, Reecha, et al.
Publicado: (2020)

How to treat intestinal obstruction due to malignant recurrence after Whipple’s resection for pancreatic head cancer: Description of 2 new endoscopic techniques
por: Mouradides, Christina, et al.
Publicado: (2017)

The Role of PPARγ in Hepatocellular Carcinoma
por: Borbath, Ivan, et al.
Publicado: (2008)

DDB2 represses epithelial-to-mesenchymal transition and sensitizes pancreatic ductal adenocarcinoma cells to chemotherapy
por: Dardare, Julie, et al.
Publicado: (2022)

Towards an updated view on the clinical management of pancreatic adenocarcinoma: Current and future perspectives
por: Pekarek, Leonel, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_45rde3csvb0etm4hkvr9op5k93